Ironwood Pharmaceuticals
Develops gastrointestinal therapies around LINZESS and apraglutide.
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 164.61M · Float —
Float — provider float is below the insider stake.
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
The provider's float is smaller than the insider stake it should exclude, so it is not shown.
Institutions13F, as of Jun 30, 2026
220 holders · 163.86M shares · 26 new positions · 98 increased · 84 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 17.79M | 10.81% | +4.43M | Aug 7, 2026 |
| Armistice Capital, LLC | 13.93M | 8.46% | −1.10M | Aug 14, 2026 |
| Sarissa Capital Management LP | 9.19M | 5.58% | 0 | Aug 14, 2026 |
| State Street Corp | 8.81M | 5.35% | +1.35M | Aug 7, 2026 |
| Bank of America Corp /DE/ | 8.68M | 5.28% | +896 | Aug 14, 2026 |
| Renaissance Technologies LLC | 7.99M | 4.86% | −67.8K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.61M | 4.01% | +511.1K | Aug 13, 2026 |
| AQR Capital Management LLC | 6.47M | 3.93% | −1.07M | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.94% | 16.15M | 13G | Aug 15, 2025 ↗ |
| Pacer US Small Cap Cash Cows ETF | 7.31% | 11.71M | 13G | May 2, 2025 ↗ |
| BlackRock, Inc. | 7.10% | 11.28M | 13G | Mar 7, 2025 ↗ |
| State Street Corporation | 6.20% | 9.92M | Oct 16, 2024 ↗ | |
| Bank of America Corp /DE/ | 6.10% | 9.96M | 13G | Apr 27, 2026 ↗ |
| Alexander J. Dennerincl. Sarissa Capital Management LP | 5.80% | 9.44M | 13D | Mar 19, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Alexander J. Denner | director | 9.44M | 5.74% | Jun 17, 2026 |
| Thomas A. MCCOURT | director, officer: Chief Executive Officer | 1.90M | 1.15% | Mar 12, 2026 |
| Michael Shetzline | officer: SVP, CMO, Head-Res&Drug | 1.18M | 0.72% | Mar 12, 2026 |
| Ronald Silver | officer: PFO & PAO | 755.3K | 0.46% | Jul 9, 2026 |
| Mark G. Currie | director | 676.9K | 0.41% | Jun 17, 2026 |
| Minardo John | officer: Chief Legal Officer | 500.5K | 0.30% | Mar 12, 2026 |
| Tammi L. Gaskins | officer: Chief Commercial Officer | 350.4K | 0.21% | Mar 12, 2026 |
| Gregory S. Martini | officer: Chief Financial Officer | 297.2K | 0.18% | Mar 12, 2026 |
| Jon R. Duane | director | 253.8K | 0.15% | Jun 17, 2026 |
| Julie McHugh | director | 250.7K | 0.15% | Jun 17, 2026 |
5 ten-percent owners hold 11.82M shares by Form 4, outside the officers-and-directors figure above · 26 people have not refiled in the last 18 months (7.88M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 7, 2026 | Ronald Silverofficer: PFO & PAO | Sale | 127,890 | $4.52 | 313,680 |
| Jun 16, 2026 | Julie McHughdirector | Sale | 21,571 | $3.73 | 250,749 |
| Mar 17, 2026 | Alexander J. Dennerdirector | Sale · 2 lots | 6,730,800 | $3.05 | 9,188,635 |
| Feb 24, 2026 | Ronald Silverofficer: Principal Accounting Officer | Sale | 12,621 | $3.66 | 252,636 |
| Feb 23, 2026 | Ronald Silverofficer: Principal Accounting Officer | Sale | 11,552 | $3.81 | 265,257 |
| Feb 24, 2026 | Gregory S. Martiniofficer: Chief Financial Officer | Sale | 11,457 | $3.66 | 160,601 |
| Feb 23, 2026 | Gregory S. Martiniofficer: Chief Financial Officer | Sale | 10,487 | $3.81 | 172,058 |
| Feb 24, 2026 | Thomas A. MCCOURTdirector, officer: Chief Executive Officer | Sale | 103,526 | $3.66 | 1,489,002 |
| Feb 23, 2026 | Thomas A. MCCOURTdirector, officer: Chief Executive Officer | Sale | 94,757 | $3.81 | 1,592,528 |
| Feb 24, 2026 | Tammi L. Gaskinsofficer: Chief Commercial Officer | Sale | 11,239 | $3.66 | 213,738 |
CongressHouse and Senate disclosures
Not reported.